Compare Nebius Group NV (NBIS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Repligen Corporation Common Stock — how do they compare? Nebius Group NV trades at $178.47 (market cap $56.24B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Nebius Group NV is far larger — about 5× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 25 Days and Repligen Corporation Common Stock for 0 Days on average.
| NBIS | RGEN | |
|---|---|---|
Market Cap | $56.24B | $11.14B |
Volume | 17,483,721 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $286.69 | $194.57 |
52-Week Low | $73.87 | $102.87 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $58.36B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $206.86, down 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 795.62, P/S 42.26) against modest profitability (net margin 3.13%, ROE 0.6%). Recent news highlights AI infrastructure growth potential but also insider selling and competitive risks.
Analyst consensus remains bullish with 82% buy ratings and a $288.67 price target, suggesting 40% upside. Key risks include high capital expenditure, negative cash flow from investing, and dependence on AI demand sustainability. The stock's outlook hinges on execution of its $37B backlog and GPU rental pricing trends.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
